MARKET

BFRI

BFRI

BIOFRONTERA INC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.950
-0.090
-1.79%
After Hours: 4.950 0 0.00% 19:59 01/14 EST
OPEN
4.910
PREV CLOSE
5.04
HIGH
5.18
LOW
4.730
VOLUME
2.11M
TURNOVER
--
52 WEEK HIGH
14.63
52 WEEK LOW
2.250
MARKET CAP
57.42M
P/E (TTM)
-3.8016
1D
5D
1M
3M
1Y
5Y
Biofrontera estimates Q4 prelim revenue growth at 7%
Biofrontera (NASDAQ:BFRI) trades 2% higher premarket after it estimates Q4 revenue to be in the range of ~$9.1 to $9.2M, an increase of ~7% from prior year period. FY21 revenue is seen ranging
Seekingalpha · 3d ago
Biofrontera Inc. Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021
WOBURN, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced preliminary, unaudited revenue for the quarter a...
GlobeNewswire · 3d ago
PSTI, NES and VORB among mid-day movers
Gainers: Splash Beverage Group (NYSE:SBEV) +37%. Virgin Orbit Holdings (NASDAQ:VORB) +26%. TSR (NASDAQ:TSRI) +27%. Accolade (NASDAQ:ACCD) +26%. BARK (NYSE:BARK) +25%. Veru (NASDAQ:VERU) +22%. Nutriband (NASDAQ:NTRB) +22%. Nuverra Environmental Solutions (N...
Seekingalpha · 5d ago
21 Stocks Moving in Tuesday's Pre-Market Session
Gainers OneSmart International Education Group Limited (NYSE: ONE) rose 39.1% to $0.2701 in pre-market trading. OneSmart International Education Group received notification from NYSE regarding delayed Form 20-F filing.
Benzinga · 5d ago
60 Biggest Movers From Yesterday
Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares surged 57.1% to close at $5.39 on Monday.
Benzinga · 6d ago
Biofrontera Inc. Announces Participation in Two Dermatology Conferences in January
WOBURN, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that it plans to participate in the following tw...
GlobeNewswire · 6d ago
Is Biofrontera a Winner in the Biopharmaceutical Industry?
StockNews.com · 01/03 12:33
3 Best Performing Healthcare IPOs in 2021
StockNews.com · 01/02 00:24
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BFRI. Analyze the recent business situations of BIOFRONTERA INC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BFRI stock price target is 15.50 with a high estimate of 20.00 and a low estimate of 11.00.
High20.00
Average15.50
Low11.00
Current 4.950
EPS
Actual
Estimate
-1.60-1.20-0.80-0.40
Q1 2020
Q1 2021
Q3 2021
Q4 2021
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.04%
Pharmaceuticals & Medical Research
+0.11%
Key Executives
Director
Loretta M. Wedge
Director
John J. Borer
Chief Executive Officer
Erica Monaco
Executive Chairman and Director
Prof. Hermann Lübbert
Director
Beth J. Hoffman
No Data
About BFRI
Biofrontera Inc is a biopharmaceutical company. The Company is specialized in the commercialization of pharmaceutical products for the treatment of dermatological conditions for the diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its products focus on the treatment of actinic keratoses, which are skin lesions that lead to skin cancer. It also markets a topical antibiotic for treatment of impetigo, a bacterial skin infection. The Company’s principal product is Ameluz, which is a prescription drug for use in combination with its medical device, the BF-RhodoLED lamp, for photodynamic therapy (PDT) in the United States for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It offers Xepi for the treatment of impetigo, a common skin infection, due to Staphylococcus aureus or streptococcus pyogenes.

Webull offers kinds of Biofrontera Inc stock information, including NASDAQ:BFRI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BFRI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BFRI stock methods without spending real money on the virtual paper trading platform.